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Abstract
Background: Five percent of all patients with breast cancer have distant metastatic disease at initial presentation.
Because metastatic breast cancer is considered to be an incurable disease, it is generally treated with a palliative
intent. Recent non-randomized studies have demonstrated that (complete) resection of the primary tumor is
associated with a significant improvement of the survival of patients with primary metastatic breast cancer.
However, other studies have suggested that the claimed survival benefit by surgery may be caused by selection
bias. Therefore, a randomized controlled trial will be performed to assess whether breast surgery in patients with
primary distant metastatic breast cancer will improve the prognosis.
Design: Randomization will take place after the diagnosis of primary distant metastatic breast cancer. Patients will
either be randomized to up front surgery of the breast tumor followed by systemic therapy or to systemic therapy,
followed by delayed local treatment of the breast tumor if clinically indicated.
Patients with primary distant metastatic breast cancer, with no prior treatment of the breast cancer, who are 18
years or older and fit enough to undergo surgery and systemic therapy are eligible. Important exclusion criteria are:
prior invasive breast cancer, surgical treatment or radiotherapy of this breast tumor before randomization,
irresectable T4 tumor and synchronous bilateral breast cancer. The primary endpoint is 2-year survival. Quality of
life and local tumor control are among the secondary endpoints.
Based on the results of prior research it was calculated that 258 patients are needed in each treatment arm,
assuming a power of 80%. Total accrual time is expected to take 60 months. An interim analysis will be performed
to assess any clinically significant safety concerns and to determine whether there is evidence that up front surgery
is clinically or statistically inferior to systemic therapy with respect to the primary endpoint.
Discussion: The SUBMIT study is a randomized controlled trial that will provide evidence on whether or not
surgery of the primary tumor in breast cancer patients with metastatic disease at initial presentation results in an
improved survival.
Trial registration: NCT01392586.
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Background
In most western countries, around five percent of all
patients with breast cancer have distant metastatic dis-
ease at initial presentation [1,2]. This accounts for 500
newly diagnosed patients each year in the Netherlands
[1]. Because metastatic breast cancer is considered to be
an incurable disease, the aim of the treatment for these
patients is to provide palliation amongst others with sys-
temic therapy. Usually, breast surgery is restricted to
those patients in whom the breast tumor is sympto-
matic. The rationale behind this strategy is based on the
fact that once distant metastases have occurred, (aggres-
sive) local therapy provides no survival advantage.
Research on the effect of systemic therapy in women
with metastatic disease has demonstrated that their
prognosis has improved significantly during the last 10
to 15 years, primarily due to increased efficacy of che-
motherapy and the introduction of targeted treatments
[2-4]. Recent retrospective studies have demonstrated
that resection of the breast tumor in patients with pri-
mary metastatic breast cancer is associated with a signif-
icant improvement of the prognosis (Table 1) [5-12].
The hazard ratios (HR) for overall survival in these stu-
dies ranged from 0,50 to 0,71 in favor of surgery of the
breast tumor. Furthermore, in studies taking surgical
resection margins into account, better survival was
observed in patients with a primary breast lesion that
had been removed with free surgical margins [5,7,13]. In
the review of Ruiterkamp et al. a pooled HR of 0.65
(95% confidence interval 0.59-0.72) was calculated for
overall survival for surgery versus no surgery, in favor of
surgery (Figure 1) [14]. Results of a stratified analysis,
done by Rapiti et al. suggest a greater effect for surgery
among women with only bone metastases at diagnosis
[7].
In all these aforementioned studies, the decision to
perform surgery could have been influenced by favorable
prognostic factors, such as younger age, the presence of
only one metastatic site or a good response to systemic
therapy. To rule out the impact of potential confoun-
ders, most studies adjusted for age, tumor size, number
and sites of metastases and hormone receptor status. In
addition, some studies also adjusted for comorbidity or
surgical margins.
More recent studies have investigated the role of addi-
tional confounding factors, such as timing of surgery,
selection bias and coding errors, and came to the con-
clusion that the survival benefit seen in patients who
were treated with a surgical resection of the primary
tumor was not so strong or may have been explained by
these confounders [15-18]. For example, in the study of
Bafford et al., the benefit of surgery seemed confined to
patients operated upon before diagnosis of metastatic
disease and there was no survival advantage in patients
who received an operation of the breast tumor after the
diagnosis of the metastatic disease had taken place. This
phenomenon was referred to as stage migration bias
[16,18]. In a study by Leung et al., the benefit from sur-
gery disappeared in the multivariate analysis when tak-
ing into account the use of chemotherapy [17]. Finally,
Table 1 Results of retrospective studies
Author Year Nr of patients Surgery (%) HR 95% CI Median survival (months)
Surgery No surgery
Not specified Lumpec Mastec
Khan [5] 2002 16023 57 0.61 0.58-0.65 - 27 32 19
Babiera [6] 2006 224 37 0.50 0.21-1.19 - -
Rapiti [7] 2006 300 42 0.60 0.4-1.0 -1 -
Fields [8] 2007 409 46 0.53 0.42-0.67 32 15
Gnerlich [9] 2007 9734 47 0.63 0.60-0.66 36 21
Blanchard [10] 2008 395 61 0.71 0.56-0.91 27 17
Cady2 [15] 2008 622 38 - - - -
Bafford [16] 2009 147 41 0.47 - 42 28
Ruiterkamp [11] 2009 728 40 0.62 0.51-0.76 31 14
Leung [17] 2009 157 33 - - 25 13
Neuman [12] 2010 186 37 0.71 0.47-1.06 40 33
Dominici2 [18] 2011 290 23 0.94 0.83-1.08 42 41
HR: Hazard ratio; 95% CI: 95% confidence interval
1 Rapiti: 5-year specific survival; 27% for surgery with negative margins, 16% for surgery with positive margins, 12% for surgery with unknown margins and 12%
for no surgery
2 Case-matched analysis
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in a study by Cady et al. coding errors in the retrospec-
tively collected dataset were found to explain part of
survival advantage [15].
Given the nature of retrospective analysis, it is not
possible to provide a definite answer to the question
whether surgical therapy of the breast tumor indeed
affects overall survival. Therefore, in the Netherlands a
randomized controlled trial (RCT) has been initiated
and will start recruiting in the second half of 2011. This
study is called, the SUBMIT trial, an acronym for ‘Sys-
temic therapy with or without Up front surgery of the
primary tumor in Breast cancer patients with distant
Metastases at Initial presenTation’. In the current paper
we will present the design of this trial.
Design
The aim of the SUBMIT study is to investigate the
effect of surgery of the primary tumor in breast cancer
patients with distant metastatic disease at initial diagno-
sis. After diagnosis of primary distant metastatic breast
cancer, patients will be randomly allocated in two
groups: A. Up front breast surgery followed by systemic
therapy; B. Systemic therapy potentially followed by
delayed local treatment of the breast tumor (Figure 2).
Patient selection criteria
The eligibility criteria for the study are:
- primary distant metastatic breast cancer (M1);
metastases diagnosed
- within one month after the diagnosis of the breast
cancer
- an anticipated survival of at least 6 months;
- a histologically proven diagnosis of the breast
tumor;
- a known hormonal and HER2Neu status;
- TNM classification: T1-T3, resectable T4 status
and N0-N3;
- performance status and comorbidity should allow
surgery and/or systemic therapy;
- age ≥ 18 years;
- written informed consent.
Exclusion criteria are:
- a primary invasive breast cancer in the medical
history;
- another malignancy within the last 10 years,
besides basal cell carcinoma of the skin or early
stage cervical cancer;
- surgical treatment and/or radiotherapy of the
breast tumor before randomization;
- irresectable T4 breast tumor;
- synchronous bilateral breast cancer.
Randomization
Centralized randomization will take place immediately
after the diagnosis of primary distant metastatic breast
cancer, using a computer-generated randomization list.
Figure 1 Pooled analyses of hazard ratios for overall mortality for surgery versus no surgery for patients with stage IV breast cancer
[14]. (1): patients with free surgical margins; (2): patients with positive surgical margins.
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Patients either randomize for up front surgery of the
breast tumor followed by systemic therapy or for sys-
temic therapy possibly followed by local treatment of
the breast tumor if clinically indicated.
The randomization will be balanced by minimization,
according to the minimization algorithm of Pocock and
Simon [19], for: centre, age (18-49, 50-69, ≥ 70 years),



































































































































Figure 2 Study design.
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tissue (lymph nodes and subcutaneous metastases) and
visceral metastases), hormonal receptor status (ER and/
or PR positive or both negative) and HER2Neu status
(overexpression yes or no).
Randomization will be performed centrally, using a
website with electronic data-entry to check treatment
eligibility.
Hypotheses
The following three hypotheses will be tested:
1. Up front breast surgery in patients with primary
distant metastatic breast cancer will result in a sig-
nificant improvement of the 2-year survival com-
pared to the survival achieved with palliative
systemic therapy followed by delayed local treatment
or systemic therapy alone.
2. Local tumor control in these patients will be
superior in case of up front breast surgery compared
to patients who receive systemic treatment with
delayed local therapy or systemic therapy alone.
3. Better local control, by the use of up front breast
surgery, results in a better quality of life in patients
with Stage IV breast cancer, compared to patients
who receive systemic treatment with delayed local
therapy or systemic therapy alone.
Ethical approval
The study is approved by the one of the Dutch Medical
Ethics Committees (METOPP; Medisch-Ethische Toets-
ing Onderzoek Patiënten en Proefpersonen, Tilburg).
The project number is NL30331.028.11. The METOPP
is an Ethical Review Committee according to the Dutch
Medical Research Involving Human Subjects Act
(WMO: Wet Medisch-Wetenschappelijk Onderzoek met
Mensen). This study will be carried out in compliance
with the Helsinki Declaration [20].
Settings and location
The study is a multicenter randomized controlled trial,
which will be conducted in the Netherlands. Both aca-
demic and regional hospitals are allowed to participate,
and already 25 centers are willing to participate.
Treatment options
During the study patients can be treated with surgery of
the primary tumor (depending on randomization), sys-
temic therapy and/or locoregional radiotherapy. The dif-
ferent treatment modalities are described below.
Surgery of the primary tumor and axillary lymph node
dissection
Patients who are randomized to up front surgery of the
breast tumor will receive a lumpectomy or mastectomy
depending on patient and tumor characteristics. Both
types of surgery may be conducted as long as the inten-
tion is a complete resection of the primary tumor,
which is defined as having succeeded in obtaining free
resection margins for the invasive component. In case of
the presence of involved margins (more than focally)
there are three options:
- to perform a re-excision or mastectomy (preferred
options in up front surgery group);
- to treat the patient with locoregional radiotherapy;
- to accept that a non-radical resection has been
performed.
What to decide belongs to the responsibility of the
treating physician; he or she is not bound by restrictions
in the protocol.
Also the choice to perform an axillary lymph node
dissection is left to the discretion of the treating physi-
cian, but is highly recommended if palpable and/or
tumor positive lymph nodes in the axillary region are
present.
If patients are randomized for systemic therapy, they
may still be candidates for surgery of the primary
tumor. In case of local progression breast surgery is
allowed at any time to gain local control, but preferen-
tially not within the initial 5-6 months of first-line sys-
temic therapy. Surgery for this group is primary
indicated when the treating physician beliefs the tumor
may cause wound problems in near future, despite use
of systemic therapy.
Locoregional radiotherapy
There are two situations where radiotherapy to the
breast or chest wall should be considered. First after an
irradical lumpectomy or mastectomy. Irradicality in this
trial is defined as involved margins for invasive breast
cancer. The second situation is in case of local progres-
sion in patients in group B where a non invasive local
therapy with radiotherapy is a treatment option instead
of surgery. In case of clinically positive axillary lymph
nodes, radiotherapy may be a viable treatment option
instead of surgery as well. In both situations a hypofrac-
tionated regimen is mandatory without too much delay
in systemic therapy, if applicable. Of note,–if considered
indicated–radiotherapy can be postponed after first-line
chemotherapy has been delivered. Concurrent radiother-
apy and chemotherapy is not allowed because of
expected excessive toxicity.
Radiotherapy may also be indicated for distant metas-
tases, such als painful bone metastases or brain
metastases.
Systemic therapy
Patients will be treated with systemic therapy according
to the guidelines from the NAtional Breast cancer
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Organization of the Netherlands (NABON) for treat-
ment of breast cancer. The choice of initial chemother-
apy, immunotherapy and endocrine therapy depends–
among others–on ER and PR and HER2Neu status,
dominant site of distant metastases, age, performance
status and comorbidity; but may also depend on the
chance to reach a complete remission for example in
minimal metastatic disease. In patients with a hormone
receptor positive tumor, hormonal treatment in indi-
cated. In case of rapid progression, chemotherapy is the
treatment of choice. In HER2Neu positive disease and
the use of an aromatase inhibitor, it is possible to add
HER2Neu targeted therapy. Chemotherapy is offered to
patients with hormone receptor negative status, with
extensive and fast growing visceral metastases and with
severe cytopenia. For this study we advice to use at least
an anthracycline, a taxane and capecitabine for the first
2-3 lines of treatment. The order is left to the discretion
of the treating physician, if necessary in combination
with targeted therapy, such as bevacizumab or HER2-
Neu targeted therapy, according to local practice.
Patients with HER2Neu overexpression, can be treated
with a combination of trastuzumab and taxanes as first-
line chemotherapy. At first line treatment one may also
choose for anthracycline containing chemotherapy, with-
out HER2Neu targeted therapy. During the following
lines of chemotherapy, continuing HER2Neu blocking
with trastuzumab or lapatinib is advised.
Primary and secondary outcome measures
The primary endpoint is the two-year survival. This is
defined as the percentage of patients who survive two
years after randomization. Secondary endpoints are
quality of life, overall survival, number of unplanned
local therapies, i.e. surgery or radiotherapy, number of
axillary lymph node dissections or axillary radiotherapy,
determination of pathological resection margin (margin
status) in patients treated by surgery of the primary
tumor and type of chemotherapy, immunotherapy and
endocrine therapy and number of regimens of systemic
therapy during the first 2 years.
Statistics
Sample size calculation
In a previous, retrospective, study performed in the
south of the Netherlands, the median survival of
patients with stage IV breast cancer who had surgery
was 31 months, as compared to 14 months for patients
who did not have surgery (P < 0.0001) [11]. In a multi-
variable Cox regression analysis, adjusting for age, per-
iod of diagnosis, T-classification, number of metastatic
sites, co-morbidity, use of locoregional radiotherapy and
use of systemic therapy, the HR of breast surgery for
overall mortality in this study was 0.62 (95% confidence
interval (CI) 0.51-0.76). In a recently published meta-
analysis, including the results of 9 retrospective studies,
the pooled HR for overall mortality was 0.65 (95% CI
0.59-0.72) [14].
We are planning a randomized controlled trial with an
equal number of patients in both treatment arms, an
accrual interval of 60 months, and additional follow-up
after the accrual interval of 18 months. We assume that
(as a result of more effective systemic treatments) the
median survival time of the patients without surgery has
improved to 18 months since 2004, which was the last
period of diagnosis included in the retrospective study
based on the data from the Eindhoven Cancer Registry
[1]. If the true hazard ratio (relative risk) of the patients
with upfront surgery relative to the patients with
immediate start of systemic therapy is 0.76 (the upper
boundary of the 95% CI of the retrospective study, per-
formed in the south of the Netherlands by Ruiterkamp et
al. [11]), we will need to study 248 patients with up front
surgery and 248 without up front surgery to be able to
reject the null hypothesis that the survival curves are
equal with a probability (power) of 0.80. The Type I error
probability associated with this test of this null hypoth-
esis is 0.05. An additional number of 20 patients will be
included to account for loss to follow-up and/or exclu-
sion after randomization because of violation of the elig-
ibility criteria; so total accrual consists of 516 patients.
Data analysis
Investigators will enter the information required by the
protocol into the Case Report Forms (CRFs). The data
from all centers will be pooled and summarized with
respect to demographic and baseline characteristics and
efficacy and safety observations. Data will be presented
for the complete intent-to-treat population. The primary
endpoint will be analyzed in a Cox regression model,
with the minimization factors as covariables.
Interim analysis
An interim analysis will be performed after 50% (258
patients) of the total required number of patients has
been included. The purpose of this interim review is to
assess any clinically significant safety concerns and to
determine whether there is evidence that up front sur-
gery (treatment A) is clinically or statistically inferior to
immediate systemic therapy without up front surgery
(treatment B), with respect to the primary endpoint. To
control the overall type I error when performing the
interim analysis, the Peto approach will be used to
ensure an overall Type I error of 5% [21,22]. A one-
sided significance level of 0.001 will be used at the
interim analysis.
Discussion
Recent studies on surgery of the breast tumor in
patients with primary distant metastatic disease are
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inconclusive regarding the effect of surgery on overall
survival. Most indicate that surgical treatment is asso-
ciated with a significantly improved overall survival
[5-12], but some state that this benefit is caused by con-
founding, induced by the retrospective study designs
[15-18]. In order to provide a definite answer with
respect to the role of surgery in primary metastatic
breast cancer, a prospective randomized controlled trial,
the SUBMIT study, is about to be initiated within The
Netherlands. If surgery is shown to be associated with
improved survival, it would also be interesting to know
more about the biological mechanisms which underly
the effect. Therefore, research on circulating tumor or
endothelial cells in blood, the immune response and the
angiogenic potential of metastases will be considered
within the trial. A grant application for a side-study, in
which circulating tumor cells (CTCs) will be enumer-
ated and characterized for HER2Neu expression and
estrogen receptor status, has already been submitted.
This side-study would enable us to address the hypoth-
esis that among patients with a HER2Neu negative pri-
mary tumor those with HER2Neu positive CTCs have a
worse outcome to standard systemic treatment com-
pared to those with HER2Neu negative CTCs. Addition-
ally, the impact of primary tumor resection on CTC
numbers will be analyzed.
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